Sign up to save your podcasts
Or
Share C-Suite COVID-19 Challenges - Ep 3
Share to email
Share to Facebook
Share to X
Share to email
Share to Facebook
Share to X
Or
C-Suite COVID-19 Challenges - Ep 3
Send us Fan Mail
Critical considerations for companies developing NASH drugs
Peter Traber focuses on ways COVID-19 can affect drug development and broader corporate strategies while our panelists weigh in on implications for clinical researchers, investors and forecasters in our third episode: C-SUITE COVID-19 CHALLENGES.
Browse Our NASH and COVID-19 Coverage https://surfingnash.com/covid-19/
View all episodes
By SurfingNASH.com
3.9
2424 ratings
Send us Fan Mail
Critical considerations for companies developing NASH drugs
Peter Traber focuses on ways COVID-19 can affect drug development and broader corporate strategies while our panelists weigh in on implications for clinical researchers, investors and forecasters in our third episode: C-SUITE COVID-19 CHALLENGES.
Browse Our NASH and COVID-19 Coverage https://surfingnash.com/covid-19/
More shows like Surfing the MASH Tsunami
View all
Freakonomics Radio
32,092 Listeners
Planet Money
30,683 Listeners
Pivot
9,634 Listeners
DOC Updates
102 Listeners
The School of Greatness
21,141 Listeners
The Curbsiders Internal Medicine Podcast
3,365 Listeners
The Daily
112,006 Listeners
Up First from NPR
56,539 Listeners
The Indicator from Planet Money
9,534 Listeners
The Peter Attia Drive
8,017 Listeners
All-In with Chamath, Jason, Sacks & Friedberg
10,195 Listeners
Consider This from NPR
6,383 Listeners
EASL Podcasts
0 Listeners
Docs Who Lift
426 Listeners
The Headlines
743 Listeners